33.27USD+1.74%Mkt Cap: 3.60B USDP/E: —Last update: 2026-05-26
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small mole…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap3.60B USD
Enterprise Value3.02B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-167.79M USD
Revenue/Share—
Last Price33.27 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees154
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-14.02
PEG—
EV/EBITDA-15.30
EV/Revenue—
P/S—
P/B7.12
EPS (TTM)-1.66
EPS (Forward)-2.33
52W Range
12.1576% of range39.96
52W High39.96 USD
52W Low12.15 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-32.13%
ROA-30.36%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-143.82M USD
CapEx (TTM)256.00K USD
FCF Margin—
FCF Yield-2.51%
Net Debt-495.77M USD
Net Debt/EBITDA2.51
Balance Sheet
Debt/Equity0.01
Current Ratio22.61
Quick Ratio22.16
Book Value/Sh4.589 USD
Cash/Share4.643 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Target (Mean)43.67 USD
Target Range20.00 USD – 52.00 USD
# Analysts12
Ownership
Shares Out.107.59M
Float67.12M
Insiders0.45%
Institutions114.00%
Short Interest
Short Ratio10.3d
Short % Float13.32%
Short % Out.9.42%
Shares Short10.13M
Short (prev mo.)9.45M
Technical
SMA 5032.30 (+3.0%)
SMA 20023.99 (+38.7%)
Beta0.25
S&P 52W Chg28.31%
Avg Vol (30d)1.20M
Avg Vol (10d)969.22K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—